Market Place
Sourcing Support
Karyopharm to Present Selinexor Data at ASH Annual Meeting
18 Nov 2024 //
PR NEWSWIRE
Karyopharm Reports Q3 2024 Financial Results & Company Progress
05 Nov 2024 //
PR NEWSWIRE
Karyopharm Announces Endpoint Change in Myelofibrosis Trial
31 Oct 2024 //
PR NEWSWIRE
Karyopharm to Report Q3 2024 Financial Results on Nov 5
31 Oct 2024 //
PR NEWSWIRE
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)
03 Sep 2024 //
PR NEWSWIRE
Karyopharm Reports Q2 2024 Results And Recent Progress
06 Aug 2024 //
PR NEWSWIRE
Karyopharm Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)
01 Jul 2024 //
PR NEWSWIRE
Karyopharm`s SIENDO Subgroups In Advanced TP53 Wild-Type Endometrial Cancer
01 Jun 2024 //
PR NEWSWIRE
Karyopharm to Participate at the Jefferies Global Healthcare Conference
29 May 2024 //
PR NEWSWIRE
Karyopharm Reports Q1 2024 Results, Highlights Company Progress
08 May 2024 //
PR NEWSWIRE
Karyopharm Shows Endometrial Cancer, Myelofibrosis Data at ASCO
24 Apr 2024 //
PR NEWSWIRE
Karyopharm to Participate at Barclays 26th Annual Global HealthcareConferences
06 Mar 2024 //
PR NEWSWIRE
Karyopharm Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Mar 2024 //
PR NEWSWIRE
Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results
29 Feb 2024 //
PR NEWSWIRE
Karyopharm Announces Preliminary Unaudited 2023 Revenue and 2024 Objectives
08 Jan 2024 //
PR NEWSWIRE
Karyopharm Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Dec 2023 //
PR NEWSWIRE
Karyopharm to Participate at Upcoming Investor Conferences
08 Nov 2023 //
PR NEWSWIRE
Karyopharm Announces Data in OS in Selinexor-Treated Patients with TP53
06 Nov 2023 //
PR NEWSWIRE
Karyopharm Reports Third Quarter 2023 Financial Results
02 Nov 2023 //
PR NEWSWIRE
Karyopharm Announces Presentations at the 65th ASH
02 Nov 2023 //
PR NEWSWIRE
Karyopharm Announces Clinical Trial Collaboration with BMS to Evaluate CC- 92480
30 Oct 2023 //
PR NEWSWIRE
Karyopharm to Present Selinexor Data at the 2023 Annual Meeting
26 Sep 2023 //
PR NEWSWIRE
Karyopharm to Participate at Upcoming Investor Conferences
05 Sep 2023 //
PR NEWSWIRE
Karyopharm Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Sep 2023 //
PR NEWSWIRE
Karyopharm cuts staff amid push to broaden use of blood cancer drug
03 Aug 2023 //
BIOPHARMADIVE
Karyopharm Reports Second Quarter 2023 Financial Results
02 Aug 2023 //
PR NEWSWIRE
Karyopharm Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Aug 2023 //
PR NEWSWIRE
Karyopharm Announces Presentation of Analyses from SIENDO Study
25 Jul 2023 //
PR NEWSWIRE
Karyopharm Announces Updated Exploratory Subgroup Analysis from SIENDO Study
19 Jul 2023 //
PR NEWSWIRE
Karyopharm Receives FDA Fast Track Designation for Selinexor
17 Jul 2023 //
PR NEWSWIRE
Karyopharm Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Jul 2023 //
PR NEWSWIRE
Karyopharm to Participate at the Jefferies Healthcare Conference
01 Jun 2023 //
PR NEWSWIRE
Karyopharm Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Jun 2023 //
PR NEWSWIRE
Karyopharm to Present New Selinexor Data at the 2023 Annual Meetings
23 May 2023 //
PR NEWSWIRE
Karyopharm Reports 1Q 2023 FYR and Highlights Recent Company Progress
04 May 2023 //
PR NEWSWIRE
Karyopharm reports interim data from eltanexor Phase I/II study
04 May 2023 //
CLINICAL TRIALS ARENA
Karyopharm Announces Presentation Data from pH 2 Study of Single-Agent Eltanexor
03 May 2023 //
BUSINESSWIRE
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule
01 May 2023 //
PR NEWSWIRE
Karyopharm Announces Presentation of Updated Phase 1 Selinexor Data
18 Apr 2023 //
PR NEWSWIRE
Karyopharm To Present Data from Phase 1 Study of Selinexor at AACR
14 Apr 2023 //
PR NEWSWIRE
Karyopharm Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 Apr 2023 //
PR NEWSWIRE
Karyopharm Announces Selinexor Data with Treatment-Naïve Myelofibrosis
14 Mar 2023 //
PR NEWSWIRE
Karyopharm to Participate at Barclays Global Healthcare Conference
08 Mar 2023 //
PR NEWSWIRE
Karyopharm and Menarini Group Receive Full Marketing Authorization for NEXPOVIO
21 Feb 2023 //
PR NEWSWIRE
Karyopharm Reports Fourth Quarter and Full Year 2022 Financial Results
15 Feb 2023 //
PR NEWSWIRE
Karyopharm to Present at SVB Securities Global Biopharma Conference
09 Feb 2023 //
PR NEWSWIRE
Karyopharm to Report Fourth Quarter and Full Year 2022 Financial Results
08 Feb 2023 //
PR NEWSWIRE
Foundation Medicine Announces Collaboration with Karyopharm for XPOVIO
10 Jan 2023 //
BUSINESSWIRE
Karyopharm Announces Preliminary Unaudited Q4 & Full Year 2022 Revenue
09 Jan 2023 //
PR NEWSWIRE
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule
03 Jan 2023 //
PR NEWSWIRE
Karyopharm Announces Investor and Analyst Event at ASH 2022 on Selinexor Data
05 Dec 2022 //
PRNEWSWIRE
Karyopharm Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Dec 2022 //
PRNEWSWIRE
Karyopharm Announces Selinexor Data in Myelofibrosis to be Presented at ASH
03 Nov 2022 //
PRNEWSWIRE
Karyopharm Reports Third Quarter 2022 Financial Results
03 Nov 2022 //
PRNEWSWIRE
Karyopharm Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Nov 2022 //
PRNEWSWIRE
Karyopharm & Menarini Announce Orphan Medicinal Designation for Selinexor
31 Oct 2022 //
PRESS RELEASE
Karyopharm to Participate at Upcoming Investor Conferences
07 Sep 2022 //
PRNEWSWIRE
Karyopharm Reports Second Quarter 2022 Financial Results
04 Aug 2022 //
PRNEWSWIRE
Karyopharm Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Aug 2022 //
PRNEWSWIRE
